Table 3.
Follow-up data
| eGFR < 15 mL/min | eGFR 15–29 mL/min | eGFR 30–59 mL/min | No CKD | p value for trend* | |
|---|---|---|---|---|---|
| Discharged alive, n | 15 | 43 | 239 | 324 | |
| Documented follow-up, n (%) | 15 (100.0) | 42 (97.7) | 234 (97.9) | 317 (97.8) | 0.85 |
| Death, n (% of patients with documented vital status) | 3 (20.0) | 8 (19.0) | 39 (16.7) | 18 (5.7) | < 0.001 |
| Events in survivors of total follow-up | |||||
| Stroke, n (%) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 3 (1.1) | 0.25 |
| TIA, n (%) | 0 (0.0) | 0 (0.0) | 1 (0.6) | 1 (0.4) | 1.0 |
| Systemic embolism, n (%) | 0 (0.0) | 1 (3.4) | 0 (0.0) | 0 (0.0) | 0.08 |
| Major adverse events | |||||
| Device dislodgement requiring action, each n (%) | |||||
| Surgery | 0 (0.0) | 1 (3.6) | 0 (0.0) | 2 (0.7) | 1.0 |
| Additional intervention | 0 (0.0) | 0 (0.0) | 1 (0.6) | 0 (0.0) | 1.0 |
| Pericardial effusion requiring action, each n (%) | |||||
| Surgery | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | – |
| Intervention | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.4) | 0.64 |
| Pulmonary embolism, n (%) | 0 (0.0) | 1 (3.4) | 5 (2.8) | 0 (0.0) | 0.04 |
| Severe bleeding, n (%) | 1 (9.1) | 0 (0.0) | 2 (1.1) | 0 (0.0) | 0.021 |
| Moderate adverse events | |||||
| Deep vein thrombosis, n (%) | 0 (0.0) | 0 (0.0) | 1 (0.6) | 1 (0.4) | 1.0 |
| Moderate bleeding, n (%) | 1 (9.1) | 1 (3.4) | 8 (4.5) | 10 (3.6) | 0.52 |
| Antithrombotic medication, each n (%) | |||||
| Anticoagulants | 1 (9.1) | 4 (13.8) | 11 (6.1) | 14 (5.1) | 0.13 |
| Antiplatelet agents | 8 (72.7) | 27 (93.1) | 152 (84.9) | 232 (83.8) | 0.74 |
| Subjective feeling of treatment success, each n (%) | |||||
| Completely | 7 (87.5) | 23 (92.0) | 141 (91.0) | 210 (88.6) | 0.53 |
| Partly | 1 (12.5) | 1 (4.0) | 8 (5.2) | 16 (6.8) | 0.77 |
| Not | 0 (0.0) | 1 (4.0) | 4 (2.6) | 11 (4.6) | 0.33 |
| Subjective feeling of safety during index hospitalisation, n (%) | 9 (100.0) | 25 (96.2) | 153 (96.2) | 237 (96.7) | 0.96 |
CKD chronic kidney disease, eGFR estimated glomerular filtration rate, TIA transitory ischemic attack
*Tested by exact Cochran–Armitage (events) or asymptotic Cochran–Armitage test; p < 0.05 is indicating a significant difference (printed in bold type)